Travere Therapeutics Inc. research snapshot
TVTX AI stock analysis currently reads Travere Therapeutics as a high-reward commercial-stage rare kidney disease biopharmaceutical whose 2025 financials improved sharply and whose FY2025 net loss narrowed by more than 90% year over year while free cash flow turned positive. At the August 3, 2026 cutoff, the latest verified close used here was $55.89 from July 31, 2026, market capitalization was about $5.20 billion, and the main open question is whether FILSPARI revenue growth, the Everest Medicines civorebrutinib licensing deal, and a path to GAAP profitability can justify a forward P/E near 22.5x on a company that has reported GAAP losses in every recent fiscal year. The next catalyst is second quarter 2026 earnings scheduled for August 4, 2026 after the market close. This is informational research and not investment advice.
Current price
$55.89
Market cap
$5.20 billion
AI score
65 / 100
Rating
High-reward commercial biotech with narrowing losses and execution risk
Trend status
Strong uptrend consolidating just below the $60.10 52-week high after a 261% one-year gain
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Travere sells targeted rare kidney disease therapies. FILSPARI is the first non-immunosuppressive therapy approved for IgA nephropathy, a large underserved market. FY2025 revenue reached $490.73 million, up about 110% year over year, but the company still reports GAAP net losses. | Medium-high |
| Moat | The moat rests on FILSPARI first-in-class status in IgAN, orphan drug exclusivity, a newly allowed US method-of-use patent that could extend exclusivity into the late 2030s, and specialty distribution. Durability depends on whether late-stage competitors can match the efficacy-safety profile. | Medium |
| Management | CEO Eric Dube and the team executed the FILSPARI launch and signed the exclusive Everest Medicines licensing deal for civorebrutinib, which closed on July 7, 2026. The planned early 2027 retirement of Chief Research Officer William Rote, with Jula Inrig moving to head of R&D, creates a key transition to monitor. | Medium |
| Financial trend | FY2025 net loss narrowed to $25.55 million from $321.55 million in 2024, and FY2025 free cash flow turned positive at about $37.78 million. Q1 2026 revenue was $127.20 million, below the $136.23 million consensus, and next quarter earnings are scheduled for August 4, 2026. | Medium-high |
| Valuation | The stock trades at about 9.7x price-to-sales on TTM revenue, about 52x book value, and a forward P/E near 22.5x based on adjusted analyst estimates. With negative GAAP EPS, conventional trailing PE valuation is not applicable. The premium assumes continued rapid revenue growth and a clear path to profitability. | Medium |
| Technical trend | TVTX is in a strong uptrend from the 52-week low of $15.03, trading near $55.89 against a 52-week high of $60.10. The stock is up about 261% over one year and sits above the 50-day moving average near $53.08 and far above the 200-day moving average near $38.36. | Medium-high |
| Risk level | Key risks are FILSPARI revenue concentration, IgAN competition (Tarpeyo, iptacopan, atrasentan), pipeline setbacks, GAAP unprofitability, reimbursement changes, shareholder dilution with shares up about 10% year over year, elevated short interest near 13% of shares outstanding, and the high one-year beta of 2.21 amplifying downside moves. | Medium-high |
| AI confidence | Medium-high confidence for commercial-stage facts, revenue and cash flow data, analyst consensus, market cap math, and major risk categories. Lower confidence for probability-adjusted pipeline valuation and long-term market share outcomes, especially with the Q2 2026 report pending on August 4, 2026. | Medium-high data confidence |
| Investment certainty | Low to medium certainty. Financials improved sharply and free cash flow is positive, but the stock already reflects aggressive expectations. Execution on the August 4 earnings report, FILSPARI market share, pipeline, and profitability will determine whether the current valuation holds. | Low to medium |
TVTX AI stock forecast
The TVTX AI stock forecast uses scenario ranges around the $55.89 July 31, 2026 close. It does not claim that AI can predict a specific future price. The bullish case requires FILSPARI to keep gaining IgAN share, the civorebrutinib deal and pipeline to add value, and the company to approach profitability. The base case assumes steady FILSPARI growth with pipeline optionality. The bearish case assumes competitive erosion, commercial disappointment, or a weak August 4 Q2 report.
$72 to $92
More likely if FILSPARI exceeds second quarter estimates on August 4, 2026, the civorebrutinib program progresses, the company reaches sustained profitability sooner than expected, and investors assign a forward P/E above the current 22.5x level.
$50 to $66
More likely if FILSPARI grows revenue at a strong but slower pace, Q2 2026 results land near consensus, GAAP losses keep narrowing, and the stock trades in a price-to-sales range consistent with recent consolidation around the $54 to $58 zone.
$30 to $42
More likely if FILSPARI faces unexpected competition or access barriers, Q2 2026 revenue misses badly, pipeline candidates fail, GAAP profitability slips further out, and the market compresses the multiple toward the 200-day moving average area near $38.36.
TVTX AI technical analysis
TVTX AI technical analysis starts from the $55.89 close on July 31, 2026 used for this static page. The stock is above its 50-day moving average near $53.08 and well above the 200-day moving average near $38.36 after a strong multi-month rally. RSI was near 51, roughly neutral after the recent pullback from the 52-week high. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $55.89 | Latest verified close used for this page as of the August 3, 2026 data cutoff. |
| Near support | $54.00 to $54.95 | Barchart lists the first support level at $54.95 and the second at $54.00, just below the 50-day moving average near $53.08. |
| Secondary support | $52.70 | Barchart lists the third support level at $52.70. A break below the $52 to $53 zone would weaken the near-term bullish setup. |
| Near resistance | $57.19 to $58.49 | Barchart lists the first resistance at $57.19 and the second at $58.49. A break above these with volume would reopen the path toward the 52-week high. |
| 52-week high resistance | $60.10 | The 52-week high at $60.10 was set in June 2026. A breakout above it would put the stock into price discovery. |
| 50-day moving average | $53.08 | TVTX is trading above the 50-day moving average, a short-term bullish condition. |
| 200-day moving average | $38.36 | The 200-day moving average is far below the current price, confirming the strong long-term uptrend. |
| Momentum | RSI about 51, neutral | The 14-day RSI near 51 suggests the stock is neither overbought nor oversold after the pullback from the 52-week high. |
| Volume | About 1.26 million shares daily average | The 20-day average volume near 1.26 million shares reflects active institutional interest in the name. |
| Volatility | IV about 70.6%, beta 2.21 | Implied volatility near 70.6% with the one-year beta at 2.21 makes TVTX a high-volatility name. The options market priced a roughly $51.30 to $60.48 expected range for the next 19 days at the cutoff. |
| Invalidation | Close below $52.70, then $53 | A close below the $52.70 third support weakens the near-term bullish setup. A sustained break of the 50-day moving average area near $53 would signal a deeper correction. |
TVTX AI trading strategy
The TVTX AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed commercial evidence, technical confirmation, position sizing, and clear invalidation levels. With the one-year beta at 2.21 and implied volatility above 70%, position sizes should be smaller than for lower-volatility names, and the pending August 4, 2026 earnings report creates a binary event risk.
Look for TVTX to hold above the $53 to $55 support zone and to break above the $57.19 and $58.49 resistance levels with above-average volume, ideally after a solid Q2 2026 report. A breakout above the $60.10 52-week high would confirm the continuation.
A daily close below $52.70 or a failed breakout from the $57 to $60 zone with rising volume should reduce confidence in the continuation setup.
If TVTX pulls back toward the 50-day moving average near $53.08 without breaking the commercial thesis, look for price stabilization and confirmation of FILSPARI fundamentals before considering re-entry.
Do not average down solely because analysts have a Strong Buy consensus. Monitor the August 4 Q2 2026 report, FILSPARI prescription trends, and quarterly revenue growth for fundamental confirmation.
Track second quarter 2026 earnings on August 4, 2026 after market close, FILSPARI revenue growth, new prescriber trends, IgAN competitor news, progress on the Everest Medicines civorebrutinib deal, and pipeline milestones such as the homocystinuria program.
Reduce position size ahead of binary events like earnings or clinical data readouts if the position exceeds the risk tolerance appropriate for a stock with beta near 2.2.
Investment research summary
Travere Therapeutics develops and commercializes therapies for rare kidney diseases. FILSPARI (sparsentan) is the first and only non-immunosuppressive treatment approved for IgA nephropathy, a chronic kidney disease with a large underserved US patient population, alongside the Thiola franchise for cystinuria.
FILSPARI holds first-in-class and orphan drug status in IgAN, and Travere received a USPTO Notice of Allowance in May 2026 for a US method-of-use patent that could extend exclusivity toward the late 2030s. The rare disease market creates meaningful prescriber and patient switching costs. Competitors including Novartis (iptacopan) and Chinook (atrasentan) remain late-stage threats that could narrow the moat.
The thesis can fail if FILSPARI revenue growth slows from competitive pressure or payer restrictions, the pending Q2 2026 report disappoints, the civorebrutinib program or pipeline candidates fail, the company cannot reach GAAP profitability and needs dilutive financing, or the stock gives back gains in a biotech sector downturn.
CEO Eric Dube has led the FILSPARI launch and signed the exclusive Everest Medicines licensing deal for civorebrutinib, which closed on July 7, 2026. The planned retirement of Chief Research Officer William Rote in early 2027, with Jula Inrig named as head of R&D, is an organizational transition to monitor. Management has guided toward a multi-billion dollar FILSPARI peak sales opportunity.
Rare kidney disease remains a growing therapeutic area with high unmet need, orphan drug incentives, and increasing pharmaceutical interest. The IgAN market is estimated in the multi-billion dollar range globally, and Travere has been expanding FILSPARI indications while adding the BTK inhibitor civorebrutinib for immune-mediated kidney diseases.
At about 9.7x TTM price-to-sales, about 52x book value, and a forward P/E near 22.5x with negative GAAP earnings, TVTX prices in continued rapid revenue growth and eventual profitability. The current level offers limited margin of safety if growth disappoints. A fair entry depends on conviction in FILSPARI market share, the August 4 earnings report, and pipeline probability.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TVTX price | $55.89 close on July 31, 2026 | StockAnalysis.com real-time quote and Barchart quote snapshot | August 3, 2026 |
| Market capitalization | $5.20 billion, verified as $55.89 x 92.99 million shares | Pineify financial_rigor.py market cap verification and StockAnalysis.com | August 3, 2026 |
| FY2025 revenue | $490.73 million, up 110.45% year over year | StockAnalysis.com financials via Fiscal.ai | August 3, 2026 |
| FY2025 net income | -$25.55 million, versus -$321.55 million in 2024 | StockAnalysis.com income statement via Fiscal.ai | August 3, 2026 |
| TTM revenue | $536.20 million, up 96.03% | StockAnalysis.com financials via Fiscal.ai | August 3, 2026 |
| TTM net income and EPS | -$21.42 million, loss per share about -$0.24 | StockAnalysis.com statistics via S&P Global Market Intelligence | August 3, 2026 |
| FY2025 free cash flow | +$37.78 million, positive for the first time in the recent period | StockAnalysis.com cash flow statement via Fiscal.ai | August 3, 2026 |
| Q1 2026 revenue and EPS | $127.20 million revenue versus $136.23 million consensus; EPS about -$0.39 to -$0.40 versus -$0.24 estimate | TradingView earnings data and Barchart most recent earnings | August 3, 2026 |
| Shares outstanding | 92.99 million, up about 10.28% year over year | StockAnalysis.com share statistics | August 3, 2026 |
| Cash and total debt | $264.68 million cash and investments versus $327.66 million total debt, net cash position of -$62.99 million | StockAnalysis.com balance sheet via Fiscal.ai | August 3, 2026 |
| Analyst consensus | Strong Buy, 15 to 16 analysts, average target $59.14, range $43 to $70 | StockAnalysis.com forecast and Barchart analyst ratings | August 3, 2026 |
| 52-week range | $15.03 to $60.10 | StockAnalysis.com and Barchart price performance | August 3, 2026 |
| Moving averages and momentum | 50-day MA about $53.08, 200-day MA about $38.36, RSI about 51 | StockAnalysis.com statistics | August 3, 2026 |
| Valuation math | 9.69x P/S on TTM revenue, 52.23x P/B, forward P/E about 22.55x, P/FCF about 131x, EV/Sales about 9.81x | StockAnalysis.com statistics and Pineify financial_rigor.py valuation verification | August 3, 2026 |
This TVTX AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong. Investing in biotech stocks carries significant risks including clinical trial failures, regulatory setbacks, and competitive dynamics.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
